These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

408 related items for PubMed ID: 8133047

  • 1. Bispecific anti-CD22/anti-CD3-ricin A chain immunotoxin is cytotoxic to Daudi lymphoma cells but not T cells in vitro and shows both A-chain-mediated and LAK-T-mediated killing.
    Shen GL, Li JL, Vitetta ES.
    J Immunol; 1994 Mar 01; 152(5):2368-76. PubMed ID: 8133047
    [Abstract] [Full Text] [Related]

  • 2. Antitumor activity of Fab' and IgG-anti-CD22 immunotoxins in disseminated human B lymphoma grown in mice with severe combined immunodeficiency disease: effect on tumor cells in extranodal sites.
    Ghetie MA, Richardson J, Tucker T, Jones D, Uhr JW, Vitetta ES.
    Cancer Res; 1991 Nov 01; 51(21):5876-80. PubMed ID: 1933855
    [Abstract] [Full Text] [Related]

  • 3. Evaluation of ricin A chain-containing immunotoxins directed against CD19 and CD22 antigens on normal and malignant human B-cells as potential reagents for in vivo therapy.
    Ghetie MA, May RD, Till M, Uhr JW, Ghetie V, Knowles PP, Relf M, Brown A, Wallace PM, Janossy G.
    Cancer Res; 1988 May 01; 48(9):2610-7. PubMed ID: 2451562
    [Abstract] [Full Text] [Related]

  • 4. Cytolysis of leukemic B-cells by T-cells activated via two bispecific antibodies.
    Bohlen H, Manzke O, Patel B, Moldenhauer G, Dörken B, von Fliedner V, Diehl V, Tesch H.
    Cancer Res; 1993 Sep 15; 53(18):4310-4. PubMed ID: 7689932
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Delivery of saporin to human B-cell lymphoma using bispecific antibody: targeting via CD22 but not CD19, CD37, or immunoglobulin results in efficient killing.
    Bonardi MA, French RR, Amlot P, Gromo G, Modena D, Glennie MJ.
    Cancer Res; 1993 Jul 01; 53(13):3015-21. PubMed ID: 7686448
    [Abstract] [Full Text] [Related]

  • 9. The in vivo anti-tumor activity of immunotoxins containing two versus one deglycosylated ricin A chains.
    Ghetie V, Engert A, Schnell R, Vitetta ES.
    Cancer Lett; 1995 Nov 27; 98(1):97-101. PubMed ID: 8529213
    [Abstract] [Full Text] [Related]

  • 10. Immunotherapeutic strategies in neuroblastoma: antitumoral activity of deglycosylated Ricin A conjugated anti-GD2 antibodies and anti-CD3xanti-GD2 bispecific antibodies.
    Manzke O, Russello O, Leenen C, Diehl V, Bohlen H, Berthold F.
    Med Pediatr Oncol; 2001 Jan 27; 36(1):185-9. PubMed ID: 11464879
    [Abstract] [Full Text] [Related]

  • 11. [Induction of cytotoxicity from human lymphocytes coated with bispecific antibody against human glioma cells].
    Nitta T, Ishizawa A, Ito M, Sato K, Yagita H, Kumura K.
    No Shinkei Geka; 1990 Nov 27; 18(11):1001-6. PubMed ID: 2247192
    [Abstract] [Full Text] [Related]

  • 12. LAK-cell-mediated cytotoxicity against tumor cell targets used to monitor the stimulatory effect of interleukin-2: cytotoxicity, target recognition and phenotype of effector cells lysing the Daudi, T24 and K562 tumor cell lines.
    Hermann GG, Zeuthen J, Claësson MH.
    Nat Immun; 1992 Nov 27; 11(1):7-16. PubMed ID: 1611282
    [Abstract] [Full Text] [Related]

  • 13. The antitumor activity of an anti-CD22 immunotoxin in SCID mice with disseminated Daudi lymphoma is enhanced by either an anti-CD19 antibody or an anti-CD19 immunotoxin.
    Ghetie MA, Tucker K, Richardson J, Uhr JW, Vitetta ES.
    Blood; 1992 Nov 01; 80(9):2315-20. PubMed ID: 1384801
    [Abstract] [Full Text] [Related]

  • 14. Cytotoxic activity of disulfide-stabilized recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) toward fresh malignant cells from patients with B-cell leukemias.
    Kreitman RJ, Margulies I, Stetler-Stevenson M, Wang QC, FitzGerald DJ, Pastan I.
    Clin Cancer Res; 2000 Apr 01; 6(4):1476-87. PubMed ID: 10778980
    [Abstract] [Full Text] [Related]

  • 15. [Analysis of cytolytic activity and cell surface phenotypes of lymphokine activated killer cells stimulated with R-IL 2 and an anti-CD 3 antibody].
    Kikuchi T, Sakai H, Nakamura N, Watanabe M, Ohno T.
    No To Shinkei; 1990 Jun 01; 42(6):575-80. PubMed ID: 2119634
    [Abstract] [Full Text] [Related]

  • 16. Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display.
    Salvatore G, Beers R, Margulies I, Kreitman RJ, Pastan I.
    Clin Cancer Res; 2002 Apr 01; 8(4):995-1002. PubMed ID: 11948105
    [Abstract] [Full Text] [Related]

  • 17. Bispecific anti-idiotype/anti-CD3 antibody therapy of murine B cell lymphoma.
    Weiner GJ, Hillstrom JR.
    J Immunol; 1991 Dec 01; 147(11):4035-44. PubMed ID: 1834746
    [Abstract] [Full Text] [Related]

  • 18. Combination of interleukin-2-stimulated lymphocytes and bispecific antibodies that efficiently lyse leukemic cells does not affect bone marrow CD34-positive stem cell function in vitro.
    Kaneko T, Fukuda J, Teramura M, Fusauchi Y, Kakui Y, Okumura K, Mizoguchi H, Oshimi K.
    Bone Marrow Transplant; 1994 Aug 01; 14(2):213-7. PubMed ID: 7527685
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.